NEW YORK, NY--(Marketwire -05/09/12)- In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of quality companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Aastrom Biosciences, Inc. (ASTM) and Geron Corporation (GERN).
Access to the full company reports can be found at:
The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a "first to invent" to a "first to file" system. The majority of countries around the world have already adopted the "first to file" system. The AIA will help benefit biotech companies "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system," BIO President and CEO Jim Greenwood stated in a press release. "Small biotechnology companies rely heavily on their patents to attract investment," and "they will benefit from the improvements to our nation's patent system made by this legislation," added Greenwood.
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to their damaged tissues.
Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, imetelstat and GRN1005. The company recently announced that it has completed planned enrollment of its randomized Phase 2 clinical trial of imetelstat, a telomerase inhibitor, as maintenance therapy following platinum-based induction therapy for patients with advanced non-small cell lung cancer (NSCLC).
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
- Geron Corporation
Five Star Equities